Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.

Poli I, Oliva GR, Mongelli G, Rotondi A, Frescura V, Arcuri G, Garufi G, Pontolillo L, Mastrantoni L, Di Monte E, Maliziola N, Fucile MA, Salvatori F, Mondello R, Palazzo A, Fabi A, Bria E, Tortora G, Orlandi A

Open source

DOI: 10.3390/jpm16030143
Published: 2026 Mar 3
Container: Journal of personalized medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/jpm16030143,
  title = {Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.},
  author = {Poli I and Oliva GR and Mongelli G and Rotondi A and Frescura V and Arcuri G and Garufi G and Pontolillo L and Mastrantoni L and Di Monte E and Maliziola N and Fucile MA and Salvatori F and Mondello R and Palazzo A and Fabi A and Bria E and Tortora G and Orlandi A},
  year = {2026},
  journal = {Journal of personalized medicine},
  doi = {10.3390/jpm16030143},
  url = {https://doi.org/10.3390/jpm16030143}
}

RIS

TY  - JOUR
TI  - Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.
AU  - Poli I
AU  - Oliva GR
AU  - Mongelli G
AU  - Rotondi A
AU  - Frescura V
AU  - Arcuri G
AU  - Garufi G
AU  - Pontolillo L
AU  - Mastrantoni L
AU  - Di Monte E
AU  - Maliziola N
AU  - Fucile MA
AU  - Salvatori F
AU  - Mondello R
AU  - Palazzo A
AU  - Fabi A
AU  - Bria E
AU  - Tortora G
AU  - Orlandi A
PY  - 2026
JO  - Journal of personalized medicine
DO  - 10.3390/jpm16030143
UR  - https://doi.org/10.3390/jpm16030143
ER  -

APA

I, P., GR, O., G, M., A, R., V, F., G, A., G, G., L, P., L, M., E, D. M., N, M., MA, F., F, S., R, M., A, P., A, F., E, B., G, T., & A, O. (2026). Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.. Journal of personalized medicine. https://doi.org/10.3390/jpm16030143

Source records

pubmed · retrieved 2026-09-27T07:43:58.953Z